More Safety Data Needed for Intravitreal Anti-VEGF Agents

Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France.
Reuters Health Information

Full Story →